Emergex Vaccines awarded SBRI contract by Innovate UK

Oxford, UK, 5 April 2017 – Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that they have been awarded a £499,825 SBRI contract with the Department of Health/Technology Strategy Board, facilitated by Innovate UK, the UK’s Innovation Agency. The ‘Vaccines for Global Development – Preclinical’ grant proceeds will be used to advance the Zika and multivalent filovirus (Ebola and Marburg) vaccine programmes.

Professor Thomas Rademacher, CEO, commented “Emergex has a grand vision to create a socially responsible company that will address the critical global need to have affordable and effective vaccines against emerging viral and bacterial outbreaks. By creating an International Repository of vaccines that can be used at the start of epidemics, we can potentially protect populations at the time of utmost need. This will also allow for field testing of human-specific T cell vaccines in relevant clinical situations. The support from Innovate UK will allow us to advance our Zika and Filovirus vaccine programmes as quickly as possible.

For more detail on the award, please see the Innovate UK announcement of the competition results (Pg. 11) here.

-Ends-

Notes to Editors

About Emergex Vaccines Holding Limited
Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. Recently it joined the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.

Find out more online at www.emergexvaccines.com.

Media Contacts:

Instinctif Partners
Sue Charles/Eileen Paul//Ashley Tapp/Emma-Jane Humphreys
Phone: +44 (0)20 7457 2020
Email: Emergex@instinctif.com

Emergex Vaccines approved as member of the Social Stock Exchange

Oxford, UK, 20 February 2017 – Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announces that they have been approved as a member of the Social Stock Exchange, society’s market for impact investing. This follows the ratification of Emergex’s impact report by the Social Stock Exchange’s independent Admissions Panel.

Emergex aim to offer a novel approach to vaccine development, using 100% synthetic components to activate the immune system; this technology is ideally suited to low resource environments such as the developing world, which are disproportionately affected by pandemics caused by these types of diseases. These vaccines will be used to create a clinical grade international vaccine repository that will act as a first line of defence against existing and newly emerging infectious outbreaks.

The Social Stock Exchange enables its accredited impact issuers to raise capital or undertake primary or secondary listings of debt or equity instruments.

-Ends-

Notes to Editors

About Emergex Vaccines Holding Limited
Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity.

Find out more online at www.emergexvaccines.com.

About the Social Stock Exchange
The Social Stock Exchange provides access to the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities. The aim of the exchange is to help these businesses connect with investors and unlock capital at scale. All issuer member companies must meet a rigorous set of criteria before joining, including the publication of an Impact Report.

The Social Stock Exchange has an agreement with NEX Exchange (formerly ISDX) to operate the Social Stock Exchange branded market segment for impact businesses.

The Social Stock Exchange Ltd (FRN: 625231) is an appointed representative of Kession Capital Limited (FRN: 582160) which is authorised and regulated by the Financial Conduct Authority (“FCA”) in the UK.
NEX is a Recognised Investment Exchange operating a regulated market and a growth market and provides a secondary market trading facility. NEX is supervised by the FCA.

For more information, please visit www.socialstockexchange.com.

Media Contacts:

Instinctif Partners
Sue Charles/Eileen Paul//Ashley Tapp/Emma-Jane Humphreys
Phone: +44 (0)20 7457 2020
Email: Emergex@instinctif.com

Emergex Vaccines provides an update on Agreement with Midatech Pharma

Oxford, UK, 22 November 2016 – Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that it has paid an upfront technology access fee and option payment of £450,000 to Midatech Pharma (AIM: MTPH, NASDAQ: MTP), under the terms of the contract. This follows the licence granted to Emergex from Midatech Pharma, which was announced in January this year.

The exclusive licensing agreement covers the use of Midatech’s proprietary gold nanoparticle platform in the development of vaccines for influenza, meningitis, bacterial pneumonia, Ebola virus, Marburg virus and viruses within the Arbovirus class, such as Zika and Dengue. This is the first deployment of Midatech’s gold nanoparticles as a conventional vaccine for infectious diseases.

Under the agreement, the licence, together with the Service and Manufacturing Agreement for both the synthesis and development manufacturing of cGMP material for clinical trials, was novated from Emergex Vaccines Limited to a related entity, Emergex Vaccines Holding Limited (“Emergex”), a private UK biotechnology company focused on developing synthetic T-cell vaccines against new and emerging infectious diseases.

Midatech will continue to be entitled to receive certain milestone and royalty payments, as well as service fees, as part of the arrangement.

Commenting on the announcement, Dr. Jim Phillips, CEO of Midatech Pharma, said: “I am pleased to see progress being made in the adaptation of our gold nanoparticle technology for use in vaccines for infectious disease, which perfectly complements our type 1 diabetes collaboration in antigen specific immunotherapy, and our early-stage internal programs which address auto-immune disease and immuno-oncology.

David Jackson of Emergex added: “The expansion of the Midatech licence with Emergex is important for the development of cross-reactive or universal vaccines against infectious agents sharing common genetic characteristics, such as flaviviruses within the Arbovirus group. There were 380 million new cases of Dengue last year and Zika is becoming a global health problem. The licence with Midatech now allows Emergex to develop vaccines that are not restricted to a single flavivirus but potentially act as a universal vaccine against Zika, Dengue and other flaviviruses. This is a continuation of our universal influenza vaccine program, which also targets genetic components common to all influenza viruses. Our synthetic T-cell mediated vaccines should also be able to safely immunize pregnant women and provide co-immunisation of the foetus, which may be required for prevention of the congenital Zika syndrome.”

-Ends-

Notes to Editors

About Emergex Vaccines Holding Limited
Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity.

Find out more online at www.emergexvaccines.com.

Media Contacts:

Instinctif Partners
Sue Charles/Eileen Paul//Ashley Tapp/Emma-Jane Humphreys
Phone: +44 (0)20 7457 2020
Email: Emergex@instinctif.com